{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:27:44Z","timestamp":1767911264772,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020594","name":"GENSIGHT BIOLOGICS PARIS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Leber hereditary optic neuropathy (LHON) is a rare, maternally inherited, mitochondrial disease resulting in sudden, progressive central vision loss. The condition affects numerous aspects of daily life, functioning and overall health-related quality of life (HRQL), which may spillover to carers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Two studies were designed to estimate patient utilities associated with varying visual acuity in LHON (study 1) and to explore carer burden (study 2). In study 1, eight LHON health state vignettes (mild vision loss [LogMAR\u2009&lt;\u20090.3] through to light perception [LogMAR\u2009\u2265\u20094]) were valued by the UK and Republic of Ireland (ROI) general pubic using the Health Utilities Index- 3 (HUI-3) and EQ-5D in an online survey (N\u2009=\u2009360) and in time trade-off interviews (TTO; n\u2009=\u2009120). In study 2, nine carers completed in-depth interviews exploring carer burden, the Care-related Quality of Life instrument (CarerQol), EQ-5D-5L and the Work Productivity and Activity Impairment Questionnaire (WPAI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Study 1 demonstrated lower utilities for people with worse visual function. Mild vision loss (LogMAR\u2009&lt;\u20090.3) was rated as 0.84 (HUI-3), 0.79 (EQ-5D) and 0.88 (TTO). Light perception (LogMAR\u2009\u2265\u20094), the most severe health state, was rated as 0.18 (HUI-3), 0.34 (EQ-5D), and 0.36 (TTO). In study 2, qualitative findings revealed substantial burden for many carers and family members. The most prominent impacts were emotional (e.g., guilt, devastation), especially related to the maternal inheritance of LHON. Impacts to carers\u2019 daily life, social life and relationships, work, and finances were also described. Standardised measures identified little impact on HRQL (EQ-5D-5L\u2009=\u20090.89), but some carer related burden (CarerQol-7D\u2009=\u200978.4). The WPAI revealed an overall work impairment of 15% and activity impairment of 37%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Findings suggest the HUI-3 may be more sensitive to the HRQL impact of vision loss compared to the EQ-5D and TTO method. The data indicate the potential value of an effective treatment for LHON. Qualitative findings describe the impact of LHON on carers. However, the burden described in the qualitative data was incongruent with quantitative measures, particularly the EQ-5D-5L. This demonstrates the value of conducting mixed-methods research and the importance of selecting measures which capture population-relevant concepts.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03737-w","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:46:55Z","timestamp":1746625615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leber hereditary optic neuropathy: utilities and carer burden from British and Irish participants"],"prefix":"10.1186","volume":"20","author":[{"given":"Claire","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Mumford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Bojakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Benedicto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"3737_CR1","unstructured":"Shemesh A, Sood G, Margolin E. Leber Hereditary Optic Neuropathy (LHON). StatPearls [Internet]. 2022 Sep 24 [cited 2022 Nov 25]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482499\/"},{"key":"3737_CR2","unstructured":"LHON Society. At what age do symptoms begin? - LHON Society [Internet]. [cited 2022 Nov 25]. Available from: https:\/\/www.lhonsociety.org\/information\/at-what-age-do-symptoms-begin"},{"key":"3737_CR3","unstructured":"LHON Society. What are the symptoms of LHON? - LHON Society [Internet]. [cited 2022 Nov 25]. Available from: https:\/\/www.lhonsociety.org\/information\/what-are-the-symptoms-of-lhon"},{"key":"3737_CR4","unstructured":"Combal JP, Chipot A, Holzinger E, Hillgenberg M, Roche M, Sargent A, et al. LHON: a qualitative study on the experiences and hopes of patients and caregivers."},{"issue":"1","key":"3737_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01724-5","volume":"16","author":"A Rabenstein","year":"2021","unstructured":"Rabenstein A, Catarino CB, Rampeltshammer V, Schindler D, Gallenm\u00fcller C, Priglinger C, et al. Smoking and alcohol, health-related quality of life and psychiatric comorbidities in Leber\u2019s Hereditary optic neuropathy mutation carriers: a prospective cohort study. Orphanet J Rare Dis. 2021;16(1):1\u201312.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3737_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/WNO.0000000000001045","volume":"40","author":"NJ Newman","year":"2020","unstructured":"Newman NJ, Carelli V, Taiel M, Yu-Wai-Man P. Visual outcomes in Leber Hereditary Optic Neuropathy patients with the m.11778G>A (MTND4) Mitochondrial DNA mutation. J Neuroophthalmol. 2020;40(4):547\u201357.","journal-title":"J Neuroophthalmol"},{"key":"3737_CR7","unstructured":"NICE. NICE health technology evaluations: the manual NICE process and methods [Internet]. 2022. Available from: www.nice.org.uk\/process\/pmg36"},{"issue":"1","key":"3737_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jval.2011.08.002","volume":"15","author":"J Tosh","year":"2012","unstructured":"Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health. 2012;15(1):118\u201327.","journal-title":"Value Health"},{"key":"3737_CR9","unstructured":"Brazier J, Rowen D. Nice DSU Technical Support Document 11: Alternatives To Eq-5d For Generating Health State Utility Values Report By The Decision Support Unit [Internet]. 2011. Available from: www.nicedsu.org.uk"},{"issue":"10","key":"3737_CR10","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"5","key":"3737_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890109002092","volume":"33","author":"WJ Furlong","year":"2001","unstructured":"Furlong WJ, Feeny DH, Torrance GW, Barr RD. The health utilities index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33(5):375\u201384.","journal-title":"Ann Med"},{"issue":"11","key":"3737_CR12","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1136\/bjophthalmol-2018-313089","volume":"103","author":"A Lloyd","year":"2019","unstructured":"Lloyd A, Piglowska N, Ciulla T, Pitluck S, Johnson S, Buessing M, et al. Estimation of impact of RPE65- mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. Br J Ophthalmol. 2019;103(11):1610\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"3737_CR13","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-list-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119(7):1050.","journal-title":"Arch Ophthalmol"},{"key":"3737_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/bmjophth-2022-001158","volume":"7","author":"PS Subramanian","year":"2022","unstructured":"Subramanian PS, Newman NJ, Moster M, Wang AG, Yu-Wai-Man P, Donahue S, et al. Study design and baseline characteristics for the reflect gene therapy trial of m.11778g>A\/ND4-LHON. BMJ Open Ophthalmol. 2022;7:1158.","journal-title":"BMJ Open Ophthalmol"},{"key":"3737_CR15","unstructured":"Abdulle I, Liu H, Gale J, Khoshenvis M, Poincenot L, Baron D, et al. Suicidal ideation and psychological symptoms in bilateral vision loss. In: 2018 COS Annual Meeting and Exhibition. Toronto; 2018."},{"issue":"1","key":"3737_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/WNO.0000000000000644","volume":"39","author":"S Cui","year":"2019","unstructured":"Cui S, Jiang H, Peng J, Wang J, Zhang X. Evaluation of vision-related quality of life in chinese patients with leber hereditary optic neuropathy and the G11778A mutation. J Neuroophthalmol. 2019;39(1):56\u20139.","journal-title":"J Neuroophthalmol"},{"key":"3737_CR17","first-page":"62","volume":"2021","author":"M Kurup","year":"2021","unstructured":"Kurup M, Ching J, Yu-Wai-Man P. Vision-related quality of life and mental health in patients with Leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2021;2021:62.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"3737_CR18","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1167\/iovs.08-3166","volume":"50","author":"MA Kirkman","year":"2009","unstructured":"Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, et al. Quality of life in patients with Leber hereditary optic neuropathy. Invest Opthalmol Visual Sci. 2009;50(7):3112.","journal-title":"Invest Opthalmol Visual Sci"},{"key":"3737_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/OPTH.S113414","volume":"11","author":"G Garcia","year":"2017","unstructured":"Garcia G, Khoshnevis M, Gale J, Frousiakis S, Hwang T, Poincenot L, et al. Profound vision loss impairs psychological well-being in young and middle-aged individuals. Clin Ophthalmol. 2017;11:417\u201327.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3737_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/0264619615616260","volume":"34","author":"J Ferguson","year":"2016","unstructured":"Ferguson J, De Abreu G. What is the lived experience for people with Leber hereditary optic neuropathy? Br J Vis Impair. 2016;34(2):111\u201322.","journal-title":"Br J Vis Impair"},{"issue":"3","key":"3737_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/WNO.0000000000001564","volume":"42","author":"BS Chen","year":"2022","unstructured":"Chen BS, Holzinger E, Taiel M, Yu-Wai-Man P. The impact of leber hereditary optic neuropathy on the quality of life of patients and their relatives: a qualitative study. J Neuroophthalmol. 2022;42(3):316\u201322.","journal-title":"J Neuroophthalmol"},{"key":"3737_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10198-013-0503-2","volume":"14","author":"BMF Janssen","year":"2013","unstructured":"Janssen BMF, Oppe M, Versteegh MM, Stolk EA. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14:5\u201313.","journal-title":"Eur J Health Econ"},{"key":"3737_CR23","unstructured":"Furlong W, Feeny D, Torrance GW, Goldsmith C, DePauw S, Boyle M, et al. Multiplicative Multi-Attribute Utility Function for the Health Utilities Index Mark 3 (HUI3) System: A Technical Report. 1998."},{"issue":"6","key":"3737_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hec.4487","volume":"31","author":"M Hern\u00e1ndez-Alava","year":"2022","unstructured":"Hern\u00e1ndez-Alava M, Pudney S. Mapping between EQ-5D-3L and EQ-5D-5L: A survey experiment on the validity of multi-instrument data. Health Econ. 2022;31(6):923\u201339.","journal-title":"Health Econ"},{"issue":"4","key":"3737_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40273-016-0477-x","volume":"35","author":"RJ Hoefman","year":"2017","unstructured":"Hoefman RJ, van Exel J, Brouwer WBF. Measuring care-related quality of life of caregivers for use in economic evaluations: CarerQol tariffs for Australia, Germany, Sweden, UK, and US. Pharmacoeconomics. 2017;35(4):469\u201378.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"3737_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"3737_CR27","unstructured":"Home [Internet]. [cited 2022 Jul 5]. Available from: http:\/\/www.reillyassociates.net\/WPAI_Scoring.html"},{"key":"3737_CR28","unstructured":"VERBI Software. MAXQDA 2020. Berlin: VERBI Software; 2019."},{"key":"3737_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","volume":"19","author":"SE Wolowacz","year":"2016","unstructured":"Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19:704\u201319. https:\/\/doi.org\/10.1016\/j.jval.2016.06.001.","journal-title":"Value Health"},{"issue":"3","key":"3737_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/bjo.85.3.327","volume":"85","author":"MM Brown","year":"2001","unstructured":"Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85(3):327\u201331.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3737_CR31","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1464-5491.2008.02430.x","volume":"25","author":"A Lloyd","year":"2008","unstructured":"Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabet Med. 2008;25(5):618\u201324.","journal-title":"Diabet Med"},{"key":"3737_CR32","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabas\u00e9s J. Self-reported population health: an international perspective based on EQ-5D. Self-Reported Population Health: An International Perspective Based on EQ-5D [Internet]. 2014 Jan 1 [cited 2022 Dec 6];1\u2013196. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500356\/","DOI":"10.1007\/978-94-007-7596-1"},{"issue":"7","key":"3737_CR33","first-page":"508","volume":"56","author":"JP Combal","year":"2015","unstructured":"Combal JP, Chipot A, Holzinger E, Hillgenberg M, Roche M, Sargent A, et al. Leber\u2019s hereditary optic neuropathy (LHON): a qualitative study on the experiences and hopes of patients and caregivers. Invest Ophthalmol Vis Sci. 2015;56(7):508\u2013508.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03737-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:47:07Z","timestamp":1746625627000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03737-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3737"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03737-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study materials were reviewed by the WCG Institutional Review Board (WCG IRB) for ethical review. The study was declared exempt from ethical review on 8th August 2022 (submission number: 1608918). All participants provided informed consent prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants consented to the publication of aggregated, de-identified study data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Julio Benedicto and Steve Bojakowski are current and previous employees of the study sponsor, GenSight Biologics. Acaster Lloyd Consulting were paid a fixed fee for their involvement in this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}